title: Non-hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: a case report.
abstract: Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide - as described for all alkylating agents - there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.
authors: Department of Medical Oncology, University of Hasselt, Diepenbeek, Belgium.
authors: Laura
authors: L
authors: Van Ginderachter
authors: Tony
authors: T
authors: Cox
authors: Ria
authors: R
authors: Drijkoningen
authors: Ruth
authors: R
authors: Achten
authors: Eric
authors: E
authors: Joosens
authors: Annelies
authors: A
authors: Maes
authors: Koen
authors: K
authors: Theunissen
authors: Jeroen
authors: J
authors: Mebis
keywords: B-cell lymphoma; Diffuse large B-cell lymphoma; Epstein-Barr virus; Lymphopenia; Temozolomide